Author

Shomron Ben-Horin

Can we rely on clinical assessment for long-term monitoring? Yes and no
Can we rely on clinical assessment for long-term monitoring? Yes and no

Shomron Ben-Horin  et al.

Lower GI symptoms in infectious disease: Introduction
Lower GI symptoms in infectious disease: Introduction

Shomron Ben-Horin

The New Treatment Platform of Subcutaneous TNF Inhibitors in Inflammatory Bowel Disease (Celltrion Healthcare)
The New Treatment Platform of Subcutaneous TNF Inhibitors in Inflammatory Bowel Disease (Celltrion Healthcare)

Shomron Ben-Horin  et al.

The refractory proctitis patient: Diagnostic pitfalls and innovative therapies
The refractory proctitis patient: Diagnostic pitfalls and innovative therapies

Shomron Ben-Horin

Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice? (Takeda)
Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice? (Takeda)

Shomron Ben-Horin  et al.

Getting the best out of anti-TNF therapy
Getting the best out of anti-TNF therapy

Shomron Ben-Horin

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL
COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

PERSONALIZED ELIMINATION DIET GUIDED BY LEUKOCYTES ACTIVATION TO FOOD FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A DOUBLE-BLIND RANDOMIZED SHAM-CONTROLLED STUDY
PERSONALIZED ELIMINATION DIET GUIDED BY LEUKOCYTES ACTIVATION TO FOOD FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A DOUBLE-BLIND RANDOMIZED SHAM-CONTROLLED STUDY

Shomron Ben-Horin  et al.

ARTIFICIAL INTELLIGENCE- AIDED COLONOSCOPY DOES NOT INCREASE ADENOMA DETECTION RATE IN ROUTINE CLINICAL PRACTICE
ARTIFICIAL INTELLIGENCE- AIDED COLONOSCOPY DOES NOT INCREASE ADENOMA DETECTION RATE IN ROUTINE CLINICAL PRACTICE

Shomron Ben-Horin  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Shomron Ben-Horin  et al.

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL
COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

Shomron Ben-Horin  et al.

QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE
QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE

Shomron Ben-Horin  et al.

UNTARGETED SERUM METABOLOME IN LONGITUDINAL CROHN'S DISEASE (CD) COHORT ENROLLED DURING REMISSION SHOWS STRONG INDIVIDUALIZED SIGNATURE AND CD-ASSOCIATED SIGNALS THAT ARE MAINTAINED ALSO IN PATIENTS WHO NORMALIZED THEIR FECAL CALPROTECTIN
UNTARGETED SERUM METABOLOME IN LONGITUDINAL CROHN'S DISEASE (CD) COHORT ENROLLED DURING REMISSION SHOWS STRONG INDIVIDUALIZED SIGNATURE AND CD-ASSOCIATED SIGNALS THAT ARE MAINTAINED ALSO IN PATIENTS WHO NORMALIZED THEIR FECAL CALPROTECTIN

Shomron Ben-Horin  et al.

SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Shomron Ben-Horin  et al.

Item 1 - 14 / 14
1